Joel Picus

26.2k total citations · 8 hit papers
224 papers, 18.1k citations indexed

About

Joel Picus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Joel Picus has authored 224 papers receiving a total of 18.1k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Oncology, 120 papers in Pulmonary and Respiratory Medicine and 65 papers in Surgery. Recurrent topics in Joel Picus's work include Prostate Cancer Treatment and Research (51 papers), Renal cell carcinoma treatment (32 papers) and Pancreatic and Hepatic Oncology Research (30 papers). Joel Picus is often cited by papers focused on Prostate Cancer Treatment and Research (51 papers), Renal cell carcinoma treatment (32 papers) and Pancreatic and Hepatic Oncology Research (30 papers). Joel Picus collaborates with scholars based in United States, Canada and France. Joel Picus's co-authors include Nicholas J. Vogelzang, Susan Halabi, Eric J. Small, Neal J. Meropol, Jorge A. García, Christopher J. Sweeney, Gary A. Koretzky, Noah M. Hahn, Robert Dreicer and Walter M. Stadler and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Joel Picus

218 papers receiving 17.8k citations

Hit Papers

Phase I Study of Single-Agent Anti–Programmed Death... 1999 2026 2008 2017 2010 2015 2008 2008 2018 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    2010 2.3k citations Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology profile →
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    2015 1.8k citations Christopher J. Sweeney, Noah M. Hahn et al. profile →
  3. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
    2008 1.5k citations Steven J. Cohen, Cornelis J.A. Punt et al. Journal of Clinical Oncology profile →
  4. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
    2008 707 citations Susan Halabi, Jonathan E. Rosenberg et al. Journal of Clinical Oncology profile →
  5. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    2018 695 citations Noah M. Hahn, Joel Picus et al. Journal of Clinical Oncology profile →
  6. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
    1999 694 citations Susan Halabi, Joel Picus et al. Journal of Clinical Oncology profile →
  7. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
    2010 679 citations Joel Picus et al. Journal of Clinical Oncology profile →
  8. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel Picus United States 55 9.3k 9.2k 4.6k 4.2k 2.5k 224 18.1k
Patrick Therasse Belgium 23 10.9k 1.2× 8.6k 0.9× 3.8k 0.8× 3.6k 0.9× 3.2k 1.3× 36 20.5k
Yoshitaka Fujii Japan 58 8.3k 0.9× 9.1k 1.0× 4.0k 0.9× 7.7k 1.8× 2.0k 0.8× 439 19.9k
J. Wanders Netherlands 38 11.1k 1.2× 7.9k 0.9× 2.8k 0.6× 4.2k 1.0× 3.0k 1.2× 132 19.6k
Daniel P. Petrylak United States 63 11.1k 1.2× 10.7k 1.2× 3.4k 0.7× 4.9k 1.1× 7.5k 3.0× 529 23.1k
Jennifer J. Knox Canada 59 7.7k 0.8× 8.3k 0.9× 3.9k 0.9× 4.7k 1.1× 4.4k 1.7× 382 17.5k
Keunchil Park South Korea 75 17.9k 1.9× 17.0k 1.9× 4.0k 0.9× 6.2k 1.5× 2.7k 1.1× 567 27.4k
Ahmad Awada Belgium 61 9.5k 1.0× 4.8k 0.5× 3.0k 0.6× 5.2k 1.2× 1.6k 0.6× 542 16.2k
David M. Nanus United States 61 5.0k 0.5× 8.2k 0.9× 3.5k 0.8× 6.2k 1.5× 1.8k 0.7× 332 14.7k
Benjamin Besse France 64 12.2k 1.3× 10.4k 1.1× 3.8k 0.8× 5.6k 1.3× 971 0.4× 708 18.8k
Walter M. Stadler United States 77 9.4k 1.0× 14.1k 1.5× 7.2k 1.6× 11.9k 2.8× 4.4k 1.7× 473 26.8k

Countries citing papers authored by Joel Picus

Since Specialization
Citations

This map shows the geographic impact of Joel Picus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Picus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Picus more than expected).

Fields of papers citing papers by Joel Picus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Picus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Picus. The network helps show where Joel Picus may publish in the future.

Co-authorship network of co-authors of Joel Picus

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Picus. A scholar is included among the top collaborators of Joel Picus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Picus. Joel Picus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pal, Sumanta K., Alice Bernard‐Tessier, Ritesh R. Kotecha, et al.. (2025). A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research. 31(10). 1847–1855. 2 indexed citations
2.
Tannir, Nizar M., Xin Gao, Ritesh R. Kotecha, et al.. (2024). Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4513–4513. 4 indexed citations
3.
Mehra, Niven, Jens Voortman, David R. Wise, et al.. (2024). Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). TPS2672–TPS2672. 4 indexed citations
4.
Brahmer, Julie R., Charles G. Drake, Ira Wollner, et al.. (2023). Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology. 41(4). 715–723. 31 indexed citations
5.
Petrylak, Daniel P., Bernhard J. Eigl, Saby George, et al.. (2023). Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(1). 63–73. 2 indexed citations
6.
Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations
7.
Lim, Kian‐Huat, Mateusz Opyrchal, Ningying Wu, et al.. (2021). Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. European Journal of Cancer. 154. 102–110. 9 indexed citations
8.
Slovin, Susan F., Syed A. Hussain, Fred Saad, et al.. (2019). Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research. 25(15). 4624–4633. 31 indexed citations
9.
Grivas, Petros, Amir Mortazavi, Joel Picus, et al.. (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 125(4). 533–540. 36 indexed citations
10.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →
11.
12.
Armstrong, Andrew J., Susan Halabi, Tim Eisen, et al.. (2016). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. The Lancet Oncology. 17(3). 378–388. 311 indexed citations
13.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations
14.
Ryan, Charles J., Mark Rosenthal, Siobhan Ng, et al.. (2012). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. Clinical Cancer Research. 19(1). 215–224. 64 indexed citations
15.
Hahn, Noah M., Walter M. Stadler, Robin Zoň, et al.. (2011). Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. Journal of Clinical Oncology. 29(12). 1525–1530. 147 indexed citations
16.
Cohen, Steven J., Cornelis J.A. Punt, Nicholas Iannotti, et al.. (2008). Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(19). 3213–3221. 1473 indexed citations breakdown →
17.
Faller, Bryan A., et al.. (2008). Anticoagulation and cardiac tamponade: Is there a relationship?. Journal of Clinical Oncology. 26(15_suppl). 9562–9562. 2 indexed citations
18.
Merchan, Jaime R., Tom R. Fitch, Joel Picus, et al.. (2007). Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. Journal of Clinical Oncology. 25(18_suppl). 5034–5034. 62 indexed citations
19.
Stadler, Walter M., Susan Halabi, Marc S. Ernstoff, et al.. (2004). A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. Journal of Clinical Oncology. 22(14_suppl). 4515–4515. 3 indexed citations
20.
Picus, Joel, et al.. (1985). A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions.. The Journal of Experimental Medicine. 162(6). 2035–2052. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Therasse Breakdown of academic impact, for papers by Yoshitaka Fujii Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Daniel P. Petrylak Breakdown of academic impact, for papers by Jennifer J. Knox Breakdown of academic impact, for papers by Keunchil Park Breakdown of academic impact, for papers by Ahmad Awada Breakdown of academic impact, for papers by David M. Nanus Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Walter M. Stadler
Rankless by CCL
2026